Caris Life Sciences vs Tempus Digital Pathology
Tempus bought Paige for $81.25M, mostly in stock, completing the deal in August 2025, and sells the Paige tools as Tempus Digital Pathology. Paige Prostate Detect is the FDA-authorized product (De Novo DEN200080) and is CE-IVDR, and it must be used with specific scanners and viewers. The breast, mitosis, lymph node, GI and PanCancer Detect tools and Paige Predict are labeled research use only. Tempus fits a pathology lab with a prostate biopsy workload.
Caris was founded in 2008, is based in Irving, Texas and trades on NASDAQ as CAI. Its range is tissue profiling plus blood tests such as Caris Assure and Caris Detect, and the vendor says it has helped more than half a million cancer patients. A melanoma team checking BRAF V600E or V600K before treatment is the kind of case MI Cancer Seek's listed companion-diagnostic indications cover.
Pathology · Reviewed November 2, 2026
Caris Life Sciences
by Caris Life Sciences · founded 2008
FDA-approved MI Cancer Seek tumor profiling test for oncologists. The GPSai tissue-of-origin AI is a lab service outside that approval.
Tempus Digital Pathology
by Tempus AI
Digital pathology AI from Paige, now part of Tempus: Paige Prostate Detect (FDA De Novo, CE-IVDR) plus research-use suites.
When to pick each one
Caris Life Sciences
- Tissue profiling plus blood tests such as Caris Assure
- Companion-diagnostic indications include BRAF V600E and V600K melanoma
Tempus Digital Pathology
- Prostate Detect FDA-authorized and CE-IVDR
- Breast, lymph node and GI tools are research use only
Score
Each row shows points earned of points available under the published rubric.
Caris Life Sciences
65of 100
Tempus Digital Pathology
38of 100
| Dimension | Caris Life Sciences | Tempus Digital Pathology | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 21 / 21 | 0 / 21 | +21 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 12 / 12 | -3.6 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
Caris Life Sciences
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Tempus Digital Pathology
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price on the Tempus pages. |
Evidence
Caris Life Sciences
FDA decisions
P240010 (opens in new tab)PMA2024-11-05
MI Cancer Seek
Peer-reviewed
5 PubMed records name Caris Life Sciences.
- An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins. (opens in new tab)
- Proactive identification of candidates for newly approved targeted therapies using a clinical decision support program. (opens in new tab)
- ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers. (opens in new tab)
Tempus Digital Pathology
FDA decisions
K241273 (opens in new tab)510(k)2025-01-09
Paige FullFocus
DEN200080 (opens in new tab)De Novo2021-09-21
Paige Prostate Detect
K201005 (opens in new tab)510(k)2020-07-15
Paige FullFocus
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Caris Life Sciences | Tempus Digital Pathology |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2008 | n/a |
| HQ | US | US |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.